TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29932311

Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg daily
Number of subjects: 296

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 296
Study: 27100801

Group type: EXPERIMENTAL
Intervention: Triangular CAF
Number of subjects: 50

Group type: COMPARATOR
Intervention: Trapezoidal CAF
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both types of CAF
Number of subjects: 50
Study: 24504788

Group type: EXPERIMENTAL
Intervention: Sports bag (with logo)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Heavier load (5 kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: School bag and neutral bag
Number of subjects: 80
Study: 21728454

Group type: EXPERIMENTAL
Intervention: Psychological distance intervention
Number of subjects: 0
Study: 19921097

Group type: EXPERIMENTAL
Intervention: Postoperative use of 0.2% chlorhexidine gluconate rinse (CHX)
Number of subjects: 28

Group type: COMPARATOR
Intervention: No postoperative use of chlorhexidine rinse (Control)
Number of subjects: 28
Study: 18573149

Group type: EXPERIMENTAL
Intervention: Self-etching primer
Number of subjects: 55

Group type: COMPARATOR
Intervention: Acid gel, semi-gel, low-viscosity gel, liquid
Number of subjects: 55
Study: 16873786

Group type: EXPERIMENTAL
Intervention: Inhaled human insulin (Exubera)
Number of subjects: 476

Group type: COMPARATOR
Intervention: Glibenclamide
Number of subjects: 476
Study: 12851181

Group type: EXPERIMENTAL
Intervention: Continuous tube feeding
Number of subjects: 105

Group type: COMPARATOR
Intervention: Intermittent bolus tube feeding
Number of subjects: 105
Study: 10793593

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 0.5 mg kg‐1 (group K1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine 1.0 mg kg‐1 (group K2)
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0.25% bupivacaine with epinephrine 1:200,000 (group B)
Number of subjects: 49
Study: 8632221

Group type: EXPERIMENTAL
Intervention: Microbial phytase from Aspergillus niger added to phytase-deactivated wheat bran
Number of subjects: 10

Group type: COMPARATOR
Intervention: Wheat bran with phytase activity
Number of subjects: 10
Study: 1425626

Group type: EXPERIMENTAL
Intervention: 1 mg ondansetron
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 4 mg ondansetron
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: All doses of ondansetron
Number of subjects: 500
Study: 3855413

Group type: EXPERIMENTAL
Intervention: Dentifrice A (1000 ppm F as Na2PO3F + 450 ppm F as NaF)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dentifrice B (1100 ppm F as NaF)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dentifrice C (1000 ppm F as Na2PO3F)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dentifrice D (1000 ppm F as SnF2)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Dentifrice E (1500 ppm F as Na2PO3F)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (0 ppm F)
Number of subjects: 22
Study: 30016396

Group type: EXPERIMENTAL
Intervention: Daily remote monitoring
Number of subjects: 664

Group type: COMPARATOR
Intervention: Control
Number of subjects: 664
Study: 29555496

Group type: EXPERIMENTAL
Intervention: e-learning tool in addition to standard patient education
Number of subjects: 416

Group type: COMPARATOR
Intervention: standard patient education
Number of subjects: 416
Study: 25526969

Group type: EXPERIMENTAL
Intervention: Vitamin C supplementation for 30 days
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24444325

Group type: EXPERIMENTAL
Intervention: Compulsory community treatment
Number of subjects: 5444

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 5444
Study: 23255861

Group type: EXPERIMENTAL
Intervention: Tea tree oil eyelid scrub (TTO)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Without tea tree oil (Control group)
Number of subjects: 106
Study: 19997983

Group type: EXPERIMENTAL
Intervention: Modified fundoplication anastomosis
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional end of esophagus to side of gastric conduit anastomosis
Number of subjects: 56
Study: 17391302

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) - 20 mg doxycycline twice daily
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD)
Number of subjects: 50
Study: 16241013

Group type: EXPERIMENTAL
Intervention: Mefenamic acid (500 mg) 2 hours before the procedure
Number of subjects: 87

Group type: COMPARATOR
Intervention: Paracervical block
Number of subjects: 87
Study: 12463579

Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 7433

Group type: EXPERIMENTAL
Intervention: Fondaparinux (administered not earlier than 6 hours postoperatively)
Number of subjects: 7433

Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 7433
Study: 9526145

Group type: EXPERIMENTAL
Intervention: Smoking Availability (told they could smoke shortly)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Smoking Stimuli (presence of smoking-related stimuli)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Probe reaction time (presence of smoking stimuli)
Number of subjects: 132
Study: 7607964

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HF XRT) with chemotherapy, total radiation dose of 59.4 Gy, in 1.10 Gy fractions, twice daily at 6‐8 h intervals.
Number of subjects: 332

Group type: EXPERIMENTAL
Intervention: Hyperfractionated radiation (HF XRT) with chemotherapy
Number of subjects: 332
Study: 2359574

Group type: EXPERIMENTAL
Intervention: Home uterine activity monitoring plus perinatal nursing support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Preterm birth prevention program including intensive education and more frequent prenatal visits
Number of subjects: 0
Study: 274808

Group type: EXPERIMENTAL
Intervention: Fissure sealing with diluted composite material on etched surfaces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fissure sealing with diluted composite material on etched-fluoridated surfaces
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control teeth (not specified intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall fissure sealing
Number of subjects: 0
Study: 31244293

Group type: EXPERIMENTAL
Intervention: Post-operative concurrent chemoradiation (CCRT)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Post-operative radiation (RT) alone
Number of subjects: 139
Study: 28663317

Group type: EXPERIMENTAL
Intervention: 50 mg prednisolone daily for 10 days
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: six-gene expression biomarker signature
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: six-gene expression signature including eosinophil and Th2 related mast cell biomarkers
Number of subjects: 55
Study: 25288047

Group type: EXPERIMENTAL
Intervention: Rheo Knee() II
Number of subjects: 10

Group type: COMPARATOR
Intervention: non‐microprocessor controlled prosthetic knee
Number of subjects: 10
Study: 24103283

Group type: EXPERIMENTAL
Intervention: CVP group A (0-1 mmHg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CVP group B (1.1-2 mmHg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CVP group C (2.1-3 mmHg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CVP group D (3.1-4 mmHg)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CVP group E (4.1-5 mmHg)
Number of subjects: 97

Group type: COMPARATOR
Intervention: CVP groups A, B, and C
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: CVP groups A and B
Number of subjects: 97
Study: 22052139

Group type: EXPERIMENTAL
Intervention: RhG‐CSF administered as a subcutaneous single dose of 10 μg/kg
Number of subjects: 40

Group type: COMPARATOR
Intervention: RhG‐CSF administered as 10 μg/kg/s.c./day once daily for 3 days
Number of subjects: 40
Study: 19536424

Group type: EXPERIMENTAL
Intervention: Tramiprosate 100 mg BID
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Tramiprosate 150 mg BID
Number of subjects: 508

Group type: COMPARATOR
Intervention: Placebo BID
Number of subjects: 508
Study: 16585294

Group type: EXPERIMENTAL
Intervention: Intervention sites (adherence to CDC recommendations)
Number of subjects: 2584

Group type: COMPARATOR
Intervention: Control sites (non-adherence to CDC recommendations)
Number of subjects: 2584

Group type: EXPERIMENTAL
Intervention: Non-adherence to CDC recommendations
Number of subjects: 2584

Group type: EXPERIMENTAL
Intervention: Adherence to CDC recommendations for second episode
Number of subjects: 2584
Study: 12559144

Group type: EXPERIMENTAL
Intervention: Cognitive intervention (distraction and reappraisal) with information pre-operatively
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (information alone)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 10558961

Group type: EXPERIMENTAL
Intervention: Combination hepatitis A/hepatitis B vaccine (3 different manufacturing consistency lots)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination hepatitis A/hepatitis B vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Separate but concurrent injections of hepatitis A and hepatitis B vaccines
Number of subjects: 0
Study: 8904559

Group type: EXPERIMENTAL
Intervention: Glucose feeding (GF)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Fructose feeding (FF)
Number of subjects: 7
Study: 1990953

Group type: EXPERIMENTAL
Intervention: Live, attenuated influenza virus by nasal drops and by aerosol
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo via the same route
Number of subjects: 14
Study: 6338856

Group type: EXPERIMENTAL
Intervention: Thioridazine hydrochloride (during administration)
Number of subjects: 40

Group type: COMPARATOR
Intervention: No thioridazine (not receiving)
Number of subjects: 40
Study: 30905065

Group type: EXPERIMENTAL
Intervention: Entecavir plus pegylated IFN-α
Number of subjects: 72
Study: 30103529

Group type: EXPERIMENTAL
Intervention: Iron and folic acid (IFA) supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient (MMN) supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medium-quantity lipid-based nutrient supplements (MQ-LNS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 25645288

Group type: EXPERIMENTAL
Intervention: FLS simulator
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: LapSim simulator
Number of subjects: 370
Study: 24643911

Group type: EXPERIMENTAL
Intervention: Metoprolol ER with AST-120 simultaneously (B)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Metoprolol ER with AST-120 1 hour later (C)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Metoprolol ER alone (A)
Number of subjects: 34
Study: 22582203

Group type: EXPERIMENTAL
Intervention: PCHMS (n=370)
Number of subjects: 742

Group type: EXPERIMENTAL
Intervention: PCHMS
Number of subjects: 742

Group type: COMPARATOR
Intervention: Waitlist (n=372)
Number of subjects: 742
Study: 19423132

Group type: EXPERIMENTAL
Intervention: Pravastatin
Number of subjects: 7832

Group type: COMPARATOR
Intervention: Control
Number of subjects: 7832
Study: 17446982

Group type: EXPERIMENTAL
Intervention: Moderate drinking
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Abstaining from alcohol
Number of subjects: 952

Group type: EXPERIMENTAL
Intervention: Heavy drinking
Number of subjects: 952
Study: 15242865

Group type: EXPERIMENTAL
Intervention: IFN beta 2.2 microg (0.05 ml)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: IFN beta 44 microg (0.5 ml)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo (0.05 ml or 0.5 ml)
Number of subjects: 209
Study: 11792479

Group type: EXPERIMENTAL
Intervention: Active neurocysticercosis with basal ganglia lesions
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Presence of lesions in putamen and caudate nuclei
Number of subjects: 120

Group type: COMPARATOR
Intervention: Comparison of lesions between hemispheres
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Clinical manifestations of basal ganglia lesions
Number of subjects: 120
Study: 10450500

Group type: EXPERIMENTAL
Intervention: FT-IR spectroscopy with chalcogenide optical fiber
Number of subjects: 0
Study: 8539153

Group type: EXPERIMENTAL
Intervention: DDD pacing
Number of subjects: 17

Group type: COMPARATOR
Intervention: VVI pacing
Number of subjects: 17
Study: 2712275

Group type: EXPERIMENTAL
Intervention: Fibreoptic bronchoscope
Number of subjects: 40

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 40
Study: 593192

Group type: EXPERIMENTAL
Intervention: gestonoroncapronate (600 mg/week)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no gestonoroncapronate)
Number of subjects: 99
Study: 31150963

Group type: EXPERIMENTAL
Intervention: Revefenacin 88 μg
Number of subjects: 1055

Group type: EXPERIMENTAL
Intervention: Revefenacin 175 μg
Number of subjects: 1055

Group type: COMPARATOR
Intervention: Tiotropium (active control)
Number of subjects: 1055
Study: 28928195

Group type: EXPERIMENTAL
Intervention: Baby mCIMT (modified constraint‐induced movement therapy)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Baby BIM (bimanual therapy)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Baby mCIMT
Number of subjects: 150

Group type: COMPARATOR
Intervention: Baby BIM
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Baby mCIMT and Baby BIM
Number of subjects: 150
Study: 25386630

Group type: EXPERIMENTAL
Intervention: Terminalia chebula mouthwash
Number of subjects: 90

Group type: COMPARATOR
Intervention: Chlorhexidine (active control)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 90
Study: 23949553

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 43
Study: 21367356

Group type: EXPERIMENTAL
Intervention: Asenapine
Number of subjects: 386

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 386
Study: 19211486

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting in women
Number of subjects: 1564

Group type: COMPARATOR
Intervention: Carotid artery stenting in men
Number of subjects: 1564
Study: 17229239

Group type: EXPERIMENTAL
Intervention: Histamine‐2 receptor antagonists
Number of subjects: 3442

Group type: COMPARATOR
Intervention: Antacids
Number of subjects: 3442

Group type: COMPARATOR
Intervention: Alginate/antacid combination
Number of subjects: 3442
Study: 15054681

Group type: EXPERIMENTAL
Intervention: Topical metronidazole (10 percent)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo carrier
Number of subjects: 20
Study: 11689731

Group type: EXPERIMENTAL
Intervention: Walking activity (3 km/d above daily lifestyle walking)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (no change in activity)
Number of subjects: 24
Study: 9244939

Group type: EXPERIMENTAL
Intervention: 0.04% bupivacaine plus adrenalin 1/2,500,000 and fentanyl 2.5 micrograms/ml (Group II)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: 0.0625% bupivacaine plus adrenalin 1/1,600,000 and fentanyl 2 micrograms/ml (Group III)
Number of subjects: 150

Group type: COMPARATOR
Intervention: No epidural analgesia (Group I)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: All groups (I, II, III)
Number of subjects: 150
Study: 7706602

Group type: EXPERIMENTAL
Intervention: 25 mg beta-carotene
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 25 mg canthaxanthin
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 25 mg beta-carotene and 25 mg canthaxanthin (combined dose)
Number of subjects: 2
Study: 3190503

Group type: EXPERIMENTAL
Intervention: Levorotatory form of 5-hydroxytryptophan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 1161368

Group type: EXPERIMENTAL
Intervention: Combination of systematic preparation, rehearsal, and supportive care conducted prior to each stressful procedure
Number of subjects: 84

Group type: COMPARATOR
Intervention: Single-session preparation conducted after admission
Number of subjects: 84

Group type: COMPARATOR
Intervention: Consistent supportive care given by one nurse at the same points as in the first condition, but including no systematic preparation or rehearsal
Number of subjects: 84
Study: 30981618

Group type: EXPERIMENTAL
Intervention: Neodymium: yttrium aluminum garnet laser treatment
Number of subjects: 40

Group type: COMPARATOR
Intervention: Topical corticosteroids
Number of subjects: 40
Study: 29261737

Group type: EXPERIMENTAL
Intervention: 1 drop of povidone-iodine 5% (PI group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3 drops of povidone-iodine 5% (PI plus group)
Number of subjects: 120
Study: 25596150

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice (6.77 mmol nitrate)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Nitrate-depleted beetroot juice (0.002 mmol nitrate; placebo)
Number of subjects: 13
Study: 24179978

Group type: COMPARATOR
Intervention: Internal socket grafting alone (ISGA)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Internal and external grafting (IEG)
Number of subjects: 78
Study: 22097347

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (GBE) (three pills, tid)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (three pills, tid)
Number of subjects: 12
Study: 18701554

Group type: EXPERIMENTAL
Intervention: Allopurinol
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 643

Group type: EXPERIMENTAL
Intervention: Probenecid
Number of subjects: 643
Study: 22429128

Group type: EXPERIMENTAL
Intervention: Slow release doxycycline gel (SRD) administered adjunctively to subgingival ultrasonic/sonic instrumentation (USI)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Slow release doxycycline gel (SRD)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Control group (no SRD)
Number of subjects: 202
Study: 15831798

Group type: EXPERIMENTAL
Intervention: 6-mo endurance-training program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: LBNP tolerance
Number of subjects: 20
Study: 12401412

Group type: EXPERIMENTAL
Intervention: Moderately intensive lifestyle management intervention (2-year duration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Eligible patients agreeing to participate in the lifestyle management program
Number of subjects: 0
Study: 9619220

Group type: EXPERIMENTAL
Intervention: Forced air warming
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (no forced air warming)
Number of subjects: 26
Study: 7609568

Group type: EXPERIMENTAL
Intervention: Intervention group (n = 127)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (n = 127)
Number of subjects: 254
Study: 2798445

Group type: EXPERIMENTAL
Intervention: 30 mg/day aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1000 mg/day aspirin
Number of subjects: 0
Study: 356370

Group type: EXPERIMENTAL
Intervention: Radical resection of the spinal lesion and insertion of autologous bone grafts (Rad. series)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Débridement of the spinal focus (Deb. series)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Rad. series
Number of subjects: 159

Group type: COMPARATOR
Intervention: Deb. series
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CNS involvement
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Paraplegic patients
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Paraparetic patients
Number of subjects: 159
Study: 11442187

Group type: EXPERIMENTAL
Intervention: Brimonidine as adjunctive therapy
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Brimonidine added to nonselective beta-blocker monotherapy
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Brimonidine added to latanoprost monotherapy
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Brimonidine added to combination regimens including latanoprost
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Quality-of-life measures
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 554

Group type: EXPERIMENTAL
Intervention: Physician rating of brimonidine adjunctive therapy
Number of subjects: 554
Study: 30797651

Group type: EXPERIMENTAL
Intervention: venlafaxine XR plus supervised exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: venlafaxine XR
Number of subjects: 15
Study: 29489818

Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate infusion
Number of subjects: 9
Study: 26352079

Group type: EXPERIMENTAL
Intervention: Bubble NCPAP
Number of subjects: 18

Group type: COMPARATOR
Intervention: Ventilator NCPAP
Number of subjects: 18
Study: 25190944

Group type: EXPERIMENTAL
Intervention: Sevoflurane 8% in oxygen
Number of subjects: 60

Group type: COMPARATOR
Intervention: Propofol 3 mg/kg
Number of subjects: 60
Study: 22825933

Group type: EXPERIMENTAL
Intervention: Tailored telephone education about prostate cancer testing
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 490
Study: 20824548

Group type: EXPERIMENTAL
Intervention: Counseling intervention (IG, n=28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (CG, n=26)
Number of subjects: 54
Study: 17355168

Group type: EXPERIMENTAL
Intervention: Spironolactone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACE inhibitors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 0
Study: 15310636

Group type: EXPERIMENTAL
Intervention: 8 mg ondansetron
Number of subjects: 34

Group type: COMPARATOR
Intervention: 4 mL saline (placebo)
Number of subjects: 34
Study: 12213884

Group type: EXPERIMENTAL
Intervention: rhIGF‐I (30 μg/kg·d) for 1 yr
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 100 μg/L IGF‐I (13 nM)
Number of subjects: 0
Study: 9797626

Group type: EXPERIMENTAL
Intervention: Nasal Continuous Positive Airway Pressure (NCPAP)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Headbox oxygen
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: NCPAP
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: NCPAP and Headbox oxygen
Number of subjects: 92
Study: 8584179

Group type: EXPERIMENTAL
Intervention: Subvocal rehearsal and inner ear/inner voice partnership in auditory imagery tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subvocal rehearsal in distinguishing voiced and unvoiced consonants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Subvocal rehearsal in making homophone judgements
Number of subjects: 0
Study: 2706415

Group type: EXPERIMENTAL
Intervention: CPH 82 (semisynthetic lignan glycosides)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: CPH 82
Number of subjects: 30